

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **TATA Health International Holdings Limited**

### **TATA 健康國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1255)**

#### **(1) RESUMPTION GUIDANCE; AND (2) CONTINUED SUSPENSION OF TRADING**

Reference is made to the announcements made by the board (the “**Board**”) of directors (the “**Directors**”) of TATA Health International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 2 April 2024, 18 April 2024, 5 June 2024 and 27 June 2024 (collectively the “**Announcements**”) pursuant to, among other things, Rules 13.09(2)(a) of the Rules (the “**Listing Rules**”) governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”). Unless otherwise defined, capitalised terms used in this announcement have the same meanings as those defined in the Announcements.

#### **RESUMPTION GUIDANCE**

The Board wishes to inform the Shareholders and potential investors of the Company that on 27 June 2024, the Company received a letter from the Stock Exchange in which the following resumption guidance (the “**Resumption Guidance**”) was set out for the Company to:

- (i) publish all outstanding financial results required under the Listing Rules and address any audit modifications;
- (ii) demonstrate the Company’s compliance with Rule 13.24; and
- (iii) inform the market of all material information for the Shareholders and potential investors to appraise the Company’s position.

The Company must meet all resumption guidance, remedy the issues causing its trading suspension and fully comply with the Listing Rules to the Stock Exchange’s satisfaction before trading in its securities is allowed to resume. For this purpose, the Company has primary responsibility to devise its action plan for resumption. The Stock Exchange may modify or supplement the Resumption Guidance if the Company’s situation changes.

Under Rule 6.01A of the Listing Rules, the Stock Exchange may cancel the listing of any securities that have been suspended from trading for a continuous period of 18 months. In the case of the Company, the 18-month period expires on 1 October 2025. If the Company fails to remedy the issues causing its trading suspension, fulfill the Resumption Guidance and fully comply with the Listing Rules to the Stock Exchange's satisfaction and resume trading in its shares by 1 October 2025, the Listing Division of the Stock Exchange will recommend the Listing Committee of the Stock Exchange to proceed with the cancellation of the Company's listing. Under Listing Rules 6.01 and 6.10, the Stock Exchange also has the right to impose a shorter specific remedial period, where appropriate.

While trading is suspended, the Company is also reminded of its obligations under the Listing Rules including, but not limited to, the following:

- (i) keep the duration of any trading suspension to the shortest possible period as required under Rule 6.05 of the Listing Rules;
- (ii) comply with its continuing obligations under the Listing Rules at all times, for example, those applying to notifiable and/or connected transactions under Chapters 14 and 14A of the Listing Rules and publication of periodic financial results and reports and, if they are not available, management accounts under Rules 13.46 to 13.49 of the Listing Rules;
- (iii) announce inside information required to be disclosed under Part XIVA of the Securities and Futures Ordinance; and
- (iv) announce quarterly updates on its developments under Rule 13.24A of the Listing Rules including, among relevant matters:
  - (A) its business operations;
  - (B) its resumption plan with details of actions that it has taken and intends to take to remedy the issues causing its trading suspension, fulfill the resumption guidance and fully comply with the Listing Rules and resume trading. The resumption plan should be accompanied with a clear timeframe in respect of each stage of work under the plan with a view that the resumption guidance can be fulfilled and trading can resume as soon as practicable and, in any event before the 18-month period expires;
  - (C) the progress of implementing its resumption plan; and
  - (D) details of any material change to the resumption plan and, in the case of delay, the reasons and impact of such delay.

The Company will make further announcement(s) as and when appropriate and in accordance with the requirements of the Listing Rules to keep the Shareholders and potential investors informed of the latest progress in complying with the Resumption Guidance. The Company shall announce further quarterly update every three (3) months from the date of this announcement until resumption or cancellation of listing (whichever is earlier).

## **QUARTERLY UPDATE ON RESUMPTION PROGRESS**

The Company is principally engaged in (i) footwear; (ii) financial services; (iii) healthcare; and (iv) online medical services business. Based on the information available to the Board, the Company's footwear business generates most of the Company's revenue for the financial year ended 31 December 2023. The Group's financial services business is continuing as usual in all material respects. For the Company's healthcare and online medical services business, the Board has been obtaining further details from the relevant parties. Notwithstanding the above, the Board is of the opinion that the healthcare and online medical services business do not cause any significant financial impact to the Company and the Group as a whole.

The Board will continue to assess and monitor the impact of the suspension of trading (if any) on the operations and financial performance of the Company, including publication of announcement(s) in relation to the business operations of the Group, as and when appropriate.

The Board is also taking appropriate steps to fulfill the other conditions in the Resumption Guidance and will update the Shareholders and potential investors of the Company on, among others, the progress as and when appropriate.

## **CONTINUED SUSPENSION OF TRADING**

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on 2 April 2024, and will remain suspended pending the release of an announcement for the 2023 Annual Results. The Company will keep the public informed of the latest developments by making further announcement(s) as and when appropriate.

**The Shareholders and potential investors of the Company are advised to invest cautiously and to be aware of the investment risks.**

By Order of the Board  
**TATA Health International Holdings Limited**

Hong Kong, 28 June 2024

*As at the date of this announcement, the Board comprises three non-executive Directors, namely, Mr. Lin Zheming, Mr. Chu Chun Ho, Dominic and Ms. Jiang Juqi; and three independent non-executive Directors, namely, Mr. Wang Jian, Mr. Tao Chi Keung and Mr. Cai Tsz Yeung.*